Cargando…
In Vitro Assessment of Fluoropyrimidine-Metabolizing Enzymes: Dihydropyrimidine Dehydrogenase, Dihydropyrimidinase, and β-Ureidopropionase
Fluoropyrimidine drugs (FPs), including 5-fluorouracil, tegafur, capecitabine, and doxifluridine, are among the most widely used anticancer agents in the treatment of solid tumors. However, severe toxicity occurs in approximately 30% of patients following FP administration, emphasizing the importanc...
Autores principales: | Hishinuma, Eiji, Gutiérrez Rico, Evelyn, Hiratsuka, Masahiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464968/ https://www.ncbi.nlm.nih.gov/pubmed/32707991 http://dx.doi.org/10.3390/jcm9082342 |
Ejemplares similares
-
Genetic Polymorphisms of Dihydropyrimidinase in a Japanese Patient with Capecitabine-Induced Toxicity
por: Hiratsuka, Masahiro, et al.
Publicado: (2015) -
Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase
por: Merloni, Filippo, et al.
Publicado: (2019) -
Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase-inhibitory fluoropyrimidine in EGFR-mutated lung adenocarcinoma: Retrospective and in vitro studies
por: IZUMI, HIROKI, et al.
Publicado: (2015) -
The Evaluation of Dihydropyrimidine Dehydrogenase Enzyme Level in the Serum of Colorectal Cancer Iraqi Males on Fluoropyrimidine-Based Chemotherapy (Capecitabine)
por: Challoob, Muhtada A, et al.
Publicado: (2023) -
Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?
por: Del Re, Marzia, et al.
Publicado: (2010)